Foundry Healthcare Long-Term Reversal Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1MRNA | MODERNA INC | Healthcare | $24.53B | 22.92% |
2SYRE | SPYRE THERAPEUTICS INC | Healthcare | $8.70B | 8.13% |
3ERAS | ERASCA INC | Healthcare | $5.96B | 5.57% |
4TXG | 10X GENOMICS INC | Healthcare | $5.55B | 5.19% |
5DFTX | DEFINIUM THERAPEUTICS INC | Healthcare | $4.83B | 4.51% |
6RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.81B | 3.56% |
7KOD | KODIAK SCIENCES INC | Healthcare | $2.67B | 2.49% |
8ATAI | ATAIBECKLEY INC | Healthcare | $2.66B | 2.48% |
9NKTR | NEKTAR THERAPEUTICS | Healthcare | $2.31B | 2.15% |
10PVLA | PALVELLA THERAPEUTICS INC | Healthcare | $2.26B | 2.11% |
11NEOG | NEOGEN CORP | Healthcare | $2.24B | 2.09% |
12IOVA | IOVANCE BIOTHERAPEUTICS INC | Healthcare | $2.23B | 2.09% |
13AGL | AGILON HEALTH INC | Healthcare | $2.17B | 2.02% |
14DMRA | DAMORA THERAPEUTICS INC | Healthcare | $1.94B | 1.81% |
15MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $1.87B | 1.75% |
16NVCR | NOVOCURE LTD | Healthcare | $1.84B | 1.72% |
17TSHA | TAYSHA GENE THERAPIES INC | Healthcare | $1.71B | 1.60% |
18TDOC | TELADOC HEALTH INC | Healthcare | $1.70B | 1.59% |
19CMPS | COMPASS PATHWAYS PLC | Healthcare | $1.67B | 1.56% |
20VIR | VIR BIOTECHNOLOGY INC | Healthcare | $1.59B | 1.49% |
21NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.59B | 1.48% |
22NVAX | NOVAVAX INC | Healthcare | $1.35B | 1.26% |
23STAA | STAAR SURGICAL CO | Healthcare | $1.32B | 1.23% |
24ABSI | ABSCI CORP | Healthcare | $1.29B | 1.21% |
25JBIO | JADE BIOSCIENCES INC | Healthcare | $1.03B | 0.96% |
26AVTX | AVALO THERAPEUTICS INC | Healthcare | $1.02B | 0.95% |
27FBRX | FORTE BIOSCIENCES INC | Healthcare | $1.00B | 0.93% |
28VOR | VOR BIOPHARMA INC | Healthcare | $980M | 0.92% |
29ANNX | ANNEXON INC | Healthcare | $950M | 0.89% |
30SLDB | SOLID BIOSCIENCES INC | Healthcare | $859M | 0.80% |
31ACRS | ACLARIS THERAPEUTICS INC | Healthcare | $793M | 0.74% |
32NGNE | NEUROGENE INC | Healthcare | $590M | 0.55% |
33STTK | SHATTUCK LABS INC | Healthcare | $577M | 0.54% |
34FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $575M | 0.54% |
35RLMD | RELMADA THERAPEUTICS INC | Healthcare | $550M | 0.51% |
36VSTM | VERASTEM INC | Healthcare | $530M | 0.50% |
37CTEV | CLARITEV CORP | Healthcare | $518M | 0.48% |
38ZURA | ZURA BIO LTD | Healthcare | $518M | 0.48% |
39ARVN | ARVINAS INC | Healthcare | $517M | 0.48% |
40DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $517M | 0.48% |
41PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $453M | 0.42% |
42TENX | TENAX THERAPEUTICS INC | Healthcare | $420M | 0.39% |
43CBIO | CRESCENT BIOPHARMA INC | Healthcare | $407M | 0.38% |
44EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $394M | 0.37% |
45STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.36% |
46ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.34% |
47LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $311M | 0.29% |
48SGHT | SIGHT SCIENCES INC | Healthcare | $274M | 0.26% |
49ZSQR | Z SQUARED INC | Healthcare | $260M | 0.24% |
50QTTB | Q32 BIO INC | Healthcare | $255M | 0.24% |
51SRZN | SURROZEN INC | Healthcare | $255M | 0.24% |
52RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $243M | 0.23% |
53KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.20% |
54SENS | SENSEONICS HOLDINGS INC | Healthcare | $214M | 0.20% |
55AGEN | AGENUS INC | Healthcare | $209M | 0.19% |
56IMUX | IMMUNIC INC | Healthcare | $207M | 0.19% |
57BDSX | BIODESIX INC | Healthcare | $204M | 0.19% |
58DTIL | PRECISION BIOSCIENCES INC | Healthcare | $203M | 0.19% |
59AMWL | AMERICAN WELL CORP | Healthcare | $199M | 0.19% |
60TNXP | TONIX PHARMACEUTICALS HOLDING CORP | Healthcare | $198M | 0.19% |
61INGN | INOGEN INC | Healthcare | $178M | 0.17% |
62KRRO | KORRO BIO INC | Healthcare | $177M | 0.17% |
63OWLT | OWLET INC | Healthcare | $162M | 0.15% |
64JYNT | JOINT CORP | Healthcare | $127M | 0.12% |
65CUE | CUE BIOPHARMA INC | Healthcare | $126M | 0.12% |
66SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $120M | 0.11% |
67VRCA | VERRICA PHARMACEUTICALS INC | Healthcare | $96M | 0.09% |
68LIXT | LIXTE BIOTECHNOLOGY HOLDINGS INC | Healthcare | $91M | 0.08% |
69RLYB | RALLYBIO CORP | Healthcare | $87M | 0.08% |
70FRMM | FORUM MARKETS INC | Healthcare | $83M | 0.08% |
71PIII | P3 HEALTH PARTNERS INC | Healthcare | $78M | 0.07% |
72ACET | ADICET BIO INC | Healthcare | $76M | 0.07% |
73ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.07% |
74CLNN | CLENE INC | Healthcare | $76M | 0.07% |
75NMAD | NOMAD POWER SOLUTIONS INC | Healthcare | $72M | 0.07% |
76SCLX | SCILEX HOLDING CO | Healthcare | $72M | 0.07% |
77AGPU | AXE COMPUTE INC | Healthcare | $72M | 0.07% |
78LONA | LEONABIO INC | Healthcare | $68M | 0.06% |
79IMA | IMAGENEBIO INC | Healthcare | $61M | 0.06% |
80EDSA | EDESA BIOTECH INC | Healthcare | $59M | 0.05% |
81MCRB | SERES THERAPEUTICS INC | Healthcare | $52M | 0.05% |
82TIL | INSTIL BIO INC | Healthcare | $50M | 0.05% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $107.04B. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 71% toward Large, 38% toward Growth. +10% unclassified (15 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 2002 → July 2026; the right-hand end is the same value as the box’s dot. 82 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 82 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 283 monthly observations · about 2.8 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 19%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (22 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 94.9% | 47.6% |
| 3 yearsp.a. | 13.9% | -3.6% |
| 5 yearsp.a. | 2.9% | -1.8% |
| 10 yearsp.a. | 4.4% | -5.2% |
| Since inceptionp.a. | 9.2% | -1.8% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 31.0% | 26.8% |
| 2025 | 26.0% | -3.3% |
| 2024 | -11.5% | -21.4% |
| 2023 | -3.3% | -27.0% |
| 2022 | -5.4% | 47.7% |
| 2021 | -10.5% | -13.8% |
| 2020 | -4.6% | -33.9% |
| 2019 | 13.9% | -9.7% |
| 2018 | -18.8% | -22.7% |
| 2017 | 51.4% | 35.8% |
| 2016 | -10.5% | 13.9% |
| 2015 | 12.4% | -2.5% |
| 2014 | 33.4% | 3.8% |
| 2013 | 67.3% | 9.8% |
| 2012 | 20.9% | -7.0% |
| 2011 | 12.6% | 15.3% |
| 2010 | 4.7% | 5.1% |
| 2009 | 15.6% | 1.2% |
| 2008 | -19.3% | 4.2% |
| 2007 | 3.0% | -0.6% |
| 2006 | 6.7% | 7.4% |
| 2005 | 6.4% | -11.0% |
| 2004 | 7.5% | -8.3% |
| 2003 | 32.1% | -12.3% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare Long-Term Reversal Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Long-Term Reversal signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.